FNY Investment Advisers LLC Has $452,000 Stock Holdings in Kenvue Inc. (NYSE:KVUE)

FNY Investment Advisers LLC increased its stake in Kenvue Inc. (NYSE:KVUE) by 167.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 21,208 shares of the company’s stock after acquiring an additional 13,274 shares during the quarter. FNY Investment Advisers LLC’s holdings in Kenvue were worth $452,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the stock. Huntington National Bank increased its position in shares of Kenvue by 26.5% during the third quarter. Huntington National Bank now owns 4,161 shares of the company’s stock worth $96,000 after buying an additional 871 shares during the period. ING Groep NV raised its position in shares of Kenvue by 23.6% in the 3rd quarter. ING Groep NV now owns 3,576,616 shares of the company’s stock worth $82,727,000 after acquiring an additional 681,954 shares in the last quarter. Saturna Capital Corp lifted its stake in shares of Kenvue by 29.9% in the 3rd quarter. Saturna Capital Corp now owns 1,334,860 shares of the company’s stock valued at $30,875,000 after purchasing an additional 307,039 shares during the period. Everence Capital Management Inc. boosted its position in shares of Kenvue by 122.1% during the 4th quarter. Everence Capital Management Inc. now owns 45,380 shares of the company’s stock valued at $969,000 after purchasing an additional 24,950 shares in the last quarter. Finally, Tyler Stone Wealth Management grew its stake in Kenvue by 134.4% during the third quarter. Tyler Stone Wealth Management now owns 49,050 shares of the company’s stock worth $1,135,000 after purchasing an additional 28,125 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Kenvue Price Performance

Kenvue stock opened at $20.97 on Tuesday. The stock has a market cap of $40.20 billion, a P/E ratio of 38.13, a P/E/G ratio of 2.02 and a beta of 1.46. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The company’s 50 day moving average price is $22.58 and its two-hundred day moving average price is $21.63. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $24.46.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.01. The company had revenue of $3.90 billion during the quarter, compared to analyst estimates of $3.92 billion. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The firm’s revenue for the quarter was down .4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.31 earnings per share. On average, equities analysts predict that Kenvue Inc. will post 1.07 earnings per share for the current year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, November 27th. Investors of record on Wednesday, November 13th were paid a $0.205 dividend. The ex-dividend date was Wednesday, November 13th. This represents a $0.82 annualized dividend and a yield of 3.91%. Kenvue’s payout ratio is 149.09%.

Analysts Set New Price Targets

A number of research firms have issued reports on KVUE. Bank of America increased their price target on Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Tuesday, October 22nd. Jefferies Financial Group began coverage on shares of Kenvue in a report on Tuesday, September 24th. They issued a “buy” rating and a $27.00 price target for the company. Barclays upgraded shares of Kenvue to a “hold” rating in a report on Thursday, December 12th. Piper Sandler raised Kenvue from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $21.00 to $26.00 in a research report on Monday, January 6th. Finally, Royal Bank of Canada upgraded Kenvue from a “hold” rating to a “moderate buy” rating in a report on Monday, December 9th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $23.09.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.